Posterior Amorphous Corneal Dystrophy

Posterior Amorphous Corneal Dystrophy is a rare eye condition that changes the very back part of the cornea. The cornea is the clear, curved “window” at the front of the eye. The “posterior” part means the back layers of this window. The word “amorphous” means the cloudy material does not have a regular shape. The word “dystrophy” means the cornea changed because of an inherited (genetic) reason, not because of infection, injury, or inflammation.

Posterior Amorphous Corneal Dystrophy—usually shortened to PACD—is a very rare, inherited eye condition that mainly affects the back half of the cornea (the clear window at the front of your eye). In PACD, there are sheet-like cloudy areas in the posterior corneal stroma (the deeper corneal layers) and often along Descemet’s membrane. These cloudy sheets are typically present in both eyes, often from early life, and tend to be non-progressive or only slowly progressive. Many people have mild vision symptoms, but some can have more noticeable blur or glare. PACD is commonly linked to autosomal dominant inheritance (if a parent has it, there’s a 50% chance a child may have it). Imaging and family studies show a strong association with a small deletion on chromosome 12q21.33 that removes several small leucine-rich proteoglycan (SLRP) genes—KERA, LUM, DCN, and EPYC—which are important for healthy corneal collagen and clarity. When these genes are missing together, the cornea’s collagen network is arranged differently, leading to the characteristic sheet-like opacities, corneal thinning, and flattening (often producing a more far-sighted prescription). rarediseases.info.nih.govOrphaPLOSPubMedPMC

In PACD, sheet-like cloudy areas form in the back stroma (a deeper layer of the cornea) and often in Descemet’s membrane (the thin layer on the inside of the cornea). These cloudy sheets often look flat and irregular, with clear spaces between them. The condition is usually present in both eyes. Many people have mild or no symptoms for years, while some notice blur, glare, or a change in glasses power. Doctors can often see these changes using a slit-lamp microscope, and they may also measure a thinner and flatter cornea than usual. OrphaNCBIEyeWiki

PACD is autosomal dominant, which means a person can inherit it if one parent carries the change. It is very rare worldwide. It can appear in several members of the same family across generations, and in rare situations it can show up for the first time in a child if the genetic change happened “de novo” (newly) in that child. PMCPubMed

---

Types

There is no official set of subtypes for PACD like “Type 1” or “Type 2.” Doctors usually describe what they see. They talk about where the cloudy sheets sit and how much of the cornea they cover. Older family reports described centro-peripheral forms (cloudy areas reaching from the center toward the periphery), peripheral-dominant forms (mostly near the edge), and even limbus-to-limbus sheets (stretching across the cornea). Some families also show a flatter cornea, more long-sightedness (hyperopia), and iris surface changes such as fine strands bridging to the inner corneal ring (Schwalbe’s line). The amount of vision change can vary widely, and progression is often slow or minimal. PubMeddisorders.eyes.arizona.edu

For practical use, clinicians often group patients by pattern and severity:

• By location: mostly central, mostly peripheral, or widespread from edge to edge.

• By density: faint sheets vs. denser sheets that scatter more light.

• By shape: irregular “sheet-like” zones with clear gaps between them.

• By corneal shape change: some patients have a flatter and thinner cornea, which can shift refraction toward hyperopia and astigmatism. PubMeddisorders.eyes.arizona.edu

---

Causes PACD

The short answer: PACD is caused by the loss of a small block of genes on chromosome 12. These genes help build and organize the corneal “scaffolding” (the extracellular matrix) so the cornea stays clear, smooth, and strong. When one copy of this block is missing, the cornea’s back layers can form those flat, cloudy sheets.

The longer, step-by-step explanation in 20 clear points (each point builds the picture):

1. A tiny missing piece of DNA on chromosome 12q21.33 sits at the heart of PACD. Scientists discovered that people with PACD are usually missing one copy of this region. This is called a heterozygous deletion. PMCIOVS

2. This missing piece includes four key genes that make small leucine-rich proteoglycans (SLRPs): KERA (keratocan), LUM (lumican), DCN (decorin), and EPYC (epiphycan). These are like tiny “organizers” that keep corneal collagen fibers evenly spaced and transparent. PMC

3. When one copy of these SLRP genes is missing, the cornea has less of these organizer proteins. With fewer organizers, the collagen framework in the back cornea becomes less regular, and cloudy sheets can appear. PMC

4. Different families can have different deletion sizes. Some deletions are around 700 kilobases, others over 1.3 megabases. Regardless of the exact size, they remove the same cluster of SLRP genes, which explains why the cornea changes in a similar way. PLOS

5. Because the change affects infrastructure proteins in the cornea, the cornea can become flatter and thinner in some cases. This shape change explains why some patients become more long-sighted (hyperopic). PubMed+1

6. The inheritance is autosomal dominant. A person needs only one altered copy to be affected. That is why multiple generations in a family can show features of PACD. PMC

7. Sometimes the deletion appears de novo (new) in a child. In that case the parents may not have any corneal findings, but the child does, because the change happened in the child’s DNA early in development. PubMed

8. The SLRP cluster genes work together, so losing them together likely has a combined effect (a “gene dosage” problem). Even though each gene has a special role, the shared outcome is a disorganized back stromal matrix. PMC

9. The KERA gene helps build keratocan, a proteoglycan important for corneal transparency and shape. Losing one copy reduces keratocan and contributes to spacing problems between collagen fibrils. PMC

10. The LUM gene makes lumican, which also stabilizes collagen fibril spacing. Less lumican means more light scatter and can support the “amorphous” sheets seen clinically. PMC

11. The DCN gene makes decorin, which binds collagen and regulates fibril growth. Reduced decorin can lead to irregular fibril assembly at the back cornea. PMC

12. The EPYC gene makes epiphycan, another SLRP with supporting roles in matrix organization. Its loss likely adds to the overall matrix imbalance. PMC

13. The deletion sometimes includes a nearby gene called CCER1. CCER1 does not explain the corneal phenotype by itself, but it sits inside the deleted segment in some families and marks how large the missing block is. PLOS

14. Before the deletion was found, scientists used linkage studies to map PACD to this chromosome region. That research pointed the way to the final discovery of the missing SLRP cluster. IOVS

15. Because the problem is structural and present from early life, PACD is usually non-inflammatory and often slow to change. Many people keep stable vision for long periods, although this varies from person to person. disorders.eyes.arizona.edu

16. The same genetic change can look different between family members. This is called variable expressivity. Some members may have very faint opacities. Others may have denser sheets or more corneal flattening and hyperopia. PubMed

17. Penetrance appears high in affected families, which means most people who carry the deletion show at least some signs when carefully examined with a slit lamp. PMC

18. Some families show mild iris changes along with the corneal findings, suggesting the genes influence tissues near the cornea’s inner border. PubMed

19. PACD is not caused by infection, trauma, or autoimmune disease. Those problems cause different patterns in the cornea and have different tests and treatments. The gene deletion is the key driver here. EyeWiki

20. Because the cause is a DNA deletion, genetic testing that looks for copy-number changes (such as chromosomal microarray, MLPA, or targeted CNV assays) is more useful than tests that only look for tiny spelling mistakes in a single gene. PMC

---

Common symptoms

1. Blurry vision that feels mild to moderate. Many people first notice it when reading or driving. The blur may feel worse in dim light because the pupil gets larger and more light hits the cloudy areas.

2. Glare and halos around bright lights at night. The sheet-like opacities can scatter light and create halos, starbursts, or hazy rings.

3. Reduced contrast or “washed-out” vision. Even if the letters are still readable, the world may look less crisp.

4. Hyperopia (long-sightedness) that shows up on a glasses prescription. This is linked to a flatter cornea in some patients.

5. Astigmatism, sometimes irregular. This means vision can be clearer in one meridian than another, and small rotations of glasses or contacts can matter.

6. Light sensitivity (photophobia) in bright daylight or under harsh LEDs because scattered light irritates the eye.

7. Glare disability while driving at night. Headlights can feel more dazzling and make lane markings harder to pick out.

8. Monocular “ghost images” or double in one eye. This happens when light refracts through uneven structures in the back cornea.

9. Eye strain after long reading or screen time due to small, constant focusing effort to overcome scatter and astigmatism.

10. Headache related to uncorrected refractive error or extra visual effort, especially in the late afternoon.

11. Feeling of dry eyes even if tear tests are normal. The sensation comes from surface glare and constant squinting rather than from true dryness in many people.

12. Fluctuating vision from day to night. Vision can seem a bit better when the pupil is small and worse when the pupil is large.

13. No typical erosions. Unlike some other corneal dystrophies, recurrent epithelial erosions are not a hallmark in PACD.

14. Usually no pain. PACD changes are structural and quiet. Pain suggests another problem, which doctors would check for.

15. Often stable for years. Some people learn they have PACD only when examined for other reasons. Others notice slow changes that can be handled with updated glasses or contact lenses. PubMeddisorders.eyes.arizona.edu

---

Diagnostic tests

(Grouped by the type of test. Not every test is needed for every person. Doctors choose based on what they see and what questions they need to answer.)

A) Physical examination (at the slit lamp and chair)

1. Detailed history. The doctor asks about vision, glare, family members with similar findings, and onset. A family pattern supports a dystrophy rather than an acquired disease. EyeWiki

2. Visual acuity with distance and near charts. This shows how sharp vision is and how much the cloudiness affects reading or driving.

3. Objective refraction and manifest refraction. This measures your exact glasses prescription, including hyperopia and astigmatism, and helps explain symptoms.

4. External eye exam and pupillary exam. The doctor checks the lids, surface, and pupil reactions to light, which should be normal in PACD.

5. Slit-lamp biomicroscopy. This is the key exam. The doctor looks for flat, sheet-like, posterior stromal opacities and clear gaps between them. They evaluate location (central vs. peripheral vs. limbus-to-limbus) and density, and they look at Descemet’s membrane and endothelium. EyeWikiOrpha

B) “Manual” or in-clinic measurements

6. Keratometry or corneal topography readings. These measure corneal curvature. In PACD some corneas are flatter than average, which goes with hyperopia. PubMed

7. Pachymetry (ultrasound or optical). This measures corneal thickness, which can be reduced in PACD. PubMed

8. Retinoscopy. The doctor watches how light moves inside the eye to check for irregular astigmatism, which can occur with corneal shape changes.

9. Intraocular pressure (IOP) by applanation. This is routine in cornea clinics. PACD is not linked to high pressure by itself, but doctors still screen for glaucoma as part of standard care. disorders.eyes.arizona.edu

10. Corneal sensation testing (Cochet-Bonnet esthesiometer or gentle cotton). Sensation is usually normal in PACD, helping separate it from some other corneal disorders.

C) Laboratory and pathological tests

11. Targeted genetic testing for copy-number changes. Tests like chromosomal microarray, qPCR, or MLPA can find the heterozygous deletion on 12q21.33 that removes KERA, LUM, DCN, and EPYC. This is the most specific lab confirmation when clinically indicated. PMC

12. Gene-panel interpretation. If a corneal dystrophy panel is ordered, the lab should ensure it can detect deletions (not just single-letter variants), because PACD is a deletion-driven condition. PMC

13. Histopathology of a corneal button (rarely needed). If someone later has a corneal transplant for another reason, the removed tissue can be stained and examined to show posterior stromal amorphous material and Descemet involvement that match PACD.

14. Immunohistochemistry for proteoglycans (research settings). Reduced SLRP signals in the stroma can support the mechanism, although this is not a routine clinical test.

15. Electron microscopy (research or specialized labs). This can show altered stromal ultrastructure and provides visual proof of matrix disorganization. It is not needed to make a clinical diagnosis.

D) Electrodiagnostic tests

(Usually normal; used if vision is worse than the cornea appearance would suggest, to check the retina or optic nerve.)

16. Full-field ERG (electroretinogram). This checks retina function. In a pure corneal dystrophy like PACD, the ERG is expected to be normal.

17. Pattern ERG. This focuses on central retinal pathways. It is usually normal in PACD and can help rule out macular disease if symptoms are disproportionate.

18. VEP (visual evoked potential). This checks the optic nerve and brain visual pathway responses. It is usually normal in PACD and helps exclude neural causes of vision loss when needed.

E) Imaging tests of the front of the eye

19. Anterior Segment OCT (AS-OCT). This non-contact scan shows the posterior stromal opacities and their depth. It helps confirm that the changes sit in the back stroma and Descemet’s membrane and can document thinner cornea. Case reports and reviews support AS-OCT as a helpful adjunct for PACD. EyeWikiLippincott Journals

20. Scheimpflug corneal tomography (e.g., Pentacam) and topography. This maps corneal curvature and thickness across thousands of points and often shows corneal flattening and reduced pachymetry in PACD. It is very useful for baseline documentation and follow-up. In some clinics, devices can combine Scheimpflug images with OCT in a single capture. In vivo confocal microscopy and specular microscopy may also be used to look closely at corneal layers and endothelial cells. PubMedThe Open Ophthalmology JournalOCULUS Main

Non-pharmacological treatments (therapies & other measures)

Important context: There is no proven cure or disease-modifying therapy for PACD. Most people are managed conservatively, focusing on optics (how light passes through the cornea) and comfort. Surgery is reserved for uncommon, more severe cases.

1. Education & monitoring – Clear explanation, regular eye exams, and baseline imaging (e.g., corneal topography, AS-OCT). Purpose: Track stability and guide decisions. Mechanism: Early detection of change improves timing of interventions. EyeWiki

2. Glasses optimization – Updated spectacles (sometimes with anti-reflective coatings). Purpose: Sharpen image and reduce glare. Mechanism: Corrects refractive error from flattening/astigmatism.

3. Rigid gas-permeable (RGP) lenses – Purpose: Create a smooth front surface, masking irregular astigmatism. Mechanism: The tear layer under the rigid lens neutralizes surface irregularities.

4. Scleral lenses – Purpose: Often the best optical quality for irregular corneas and glare. Mechanism: A fluid reservoir vaults the cornea, creating a smooth optical surface. Modern OptometryGlobal Vision Rehabilitation Center

5. Custom soft toric or hybrid lenses – Purpose: Comfort plus some irregularity control. Mechanism: Lens optics partially neutralize astigmatic blur.

6. Tinted/filtered lenses – Purpose: Reduce light scatter and halos. Mechanism: Tints/filters lower stray light from posterior opacities.

7. Task lighting and anti-glare strategies – Purpose: Improve contrast for reading/computer work/night driving. Mechanism: Optimizes light environment to reduce scatter.

8. Lubrication strategies without medications – Saline rinses or non-medicated eye surface hydration strategies. Purpose: Comfort, better contact lens tolerance. Mechanism: Improves tear film regularity (note: preserved/artificial tears are “drugs”; see medication section).

9. Humidifier & blink hygiene – Purpose: Reduce dryness-related blur and lens awareness. Mechanism: Moist air and mindful blinking stabilize the tear film.

10. Workplace/visual ergonomics – Purpose: Reduce fatigue and glare. Mechanism: Adjust monitor height, matte screens, larger fonts, frequent breaks.

11. UV-blocking eyewear – Purpose: General ocular protection outdoors. Mechanism: Limits UV exposure that can worsen light sensitivity (disease-modifying effect not proven).

12. Protective eyewear for sports/DIY – Purpose: Prevent trauma to a thinned cornea. Mechanism: Physical barrier against impact or debris.

13. Contact lens hygiene optimization – Purpose: Prevent irritation/infection. Mechanism: Proper cleaning systems improve comfort and safety, helping patients keep using RGP/scleral lenses.

14. Bandage contact lens (device use) – Purpose: Temporary comfort support if the surface is irritated or after minor procedures. Mechanism: Physical “bandage,” not a medicine.

15. Low-vision aids – Magnifiers, high-contrast apps. Purpose: Enhance function if vision is reduced. Mechanism: Amplifies and optimizes remaining vision.

16. Counseling about refractive surgery – Purpose: Avoid inappropriate procedures. Mechanism: LASIK/PRK are generally discouraged in thin/flat corneas; not a treatment for PACD.

17. Family counseling/testing referral – Purpose: Because of dominant inheritance. Mechanism: Identify affected relatives early; offer genetic counseling. PLOSPubMed

18. Photography/AS-OCT follow-up – Purpose: Objective tracking. Mechanism: Compares images over time to confirm stability or change. EyeWiki

19. Night-driving strategies – Purpose: Manage halos and glare. Mechanism: Route planning, anti-glare lenses, avoiding oncoming headlight glare.

20. Care coordination – Purpose: Seamless transition if surgery is ever needed. Mechanism: Early referral to a cornea specialist familiar with rare dystrophies. EyeWiki

---

Drug treatments

Bottom line: There are no medicines that cure or reverse PACD. Drug therapy—when used—is supportive (comfort, surface health, peri-operative care) or treats co-existing problems (e.g., dry eye, allergy). Always use medications only under an eye-care professional’s guidance.

1. Preservative-free artificial tears (drops) – e.g., carboxymethylcellulose 0.5% or similar, 1–6×/day or as directed. Purpose: Comfort, smooth tear film (better optics). Mechanism: Lubrication reduces tear break-up and blur.

2. Lubricating gel/ointment (night) – thin strip qHS. Purpose: Morning comfort and clearer first vision. Mechanism: Longer-lasting surface protection.

3. Topical anti-inflammatory for dry eye (cyclosporine 0.05–0.1%) – BID, weeks to months. Purpose: Reduce surface inflammation if clinically diagnosed. Mechanism: Lowers T-cell–mediated inflammation to stabilize tears.

4. Topical lifitegrast 5% – BID. Purpose/Mechanism: Improves symptoms by blocking LFA-1/ICAM-1 interaction in dry eye disease.

5. Short course low-risk steroid (e.g., loteprednol 0.5%) – QID then taper, only short-term if inflammation from lens wear/surface irritation exists. Mechanism: Potent anti-inflammatory; risks include pressure rise and cataract with misuse.

6. Topical antihistamine/mast-cell stabilizer (e.g., olopatadine) – QD–BID in allergy season. Purpose: Relieve itch/tearing that worsen blur.

7. Hypertonic saline 5% drops/ointment – QID/HS when there’s epithelial edema after procedures or lens overwear (note: PACD itself typically lacks edema; this is context-dependent). webeye.ophth.uiowa.edu

8. Topical antibiotic (e.g., moxifloxacin 0.5%) – QID after surgery or with epithelial defects, per surgeon. Purpose: Infection prophylaxis.

9. Cycloplegic (e.g., cyclopentolate 1%) – BID–TID short-term for post-procedural photophobia. Purpose: Comfort by relaxing the ciliary muscle.

10. IOP-lowering drops (e.g., timolol 0.5%) – BID only if steroid-related ocular hypertension develops after surgery. Mechanism: Decreases aqueous production.

Safety note: Doses above are typical examples for common eye conditions, not PACD-specific prescriptions. Your clinician will personalize them to your eye, lens use, and any surgery.

---

Dietary “molecular” supplements

There is no supplement proven to cure or halt PACD. Some people use general eye-surface or antioxidant support. Discuss all supplements with your clinician, especially if you’re pregnant, nursing, on blood thinners, or have chronic conditions.

1. Omega-3 fatty acids (fish/algal oil) – ~1,000 mg/day EPA+DHA (typical). Function: Tear stability in some dry eye patients; systemic anti-inflammatory effects. Mechanism: Modulates lipid layer and inflammatory mediators.

2. Lutein (10 mg/day) + Zeaxanthin (2 mg/day) – Function: Antioxidant support for retinal/ocular tissues; general visual function support. Mechanism: Quenches oxidative stress.

3. Vitamin C (ascorbic acid 250–500 mg/day) – Function: Collagen co-factor; antioxidant. Mechanism: Supports extracellular matrix health.

4. Zinc (up to 25 mg/day) – Function: Enzymatic co-factor in ocular tissues. Mechanism: Antioxidant enzyme support (avoid excess).

5. Vitamin A (dietary, not high-dose pills) – Function: Epithelial/tear mucin support. Mechanism: Goblet cell function; avoid toxicity (no megadoses).

6. Vitamin E (≤200 IU/day) – Function: Antioxidant; works with vitamin C. Mechanism: Lipid peroxidation protection.

7. N-acetylcysteine (NAC 600 mg/day) – Function: Mucolytic/antioxidant; sometimes used off-label in ocular surface complaints.

8. Curcumin (with piperine; ~500 mg/day) – Function: Systemic anti-inflammatory potential; discuss drug interactions.

9. Hyaluronic acid (oral) – Function: May aid joint/ocular surface hydration; evidence mixed.

10. Balanced multivitamin with minerals – Function: General nutritional sufficiency when diet is limited.

Evidence reminder: Supplements may help comfort or general eye health. None have been proven to change the course of PACD.

---

Regenerative / stem-cell” options

There are no approved “immunity boosters” or stem-cell drugs for PACD. Using immune-boosting pills for PACD is not supported. Here’s an honest, safety-first summary:

1. Autologous serum tears (AST) – Regenerative-adjacent, clinical (made from your blood). Use: Severe dry eye or surface problems that limit lens wear. Dosing: Often QID–8×/day, individualized. Mechanism: Delivers natural growth factors to the ocular surface. (Not a PACD cure.)

2. Platelet-rich plasma (PRP) eye drops – Regenerative-adjacent, clinical in some centers. Use: Epithelial healing/surface comfort. Mechanism: Platelet growth factors. (Not disease-modifying for PACD.)

3. Self-retained amniotic membrane (device/biologic) – Use: Surface healing after abrasions or procedures; not a PACD treatment. Mechanism: Anti-inflammatory and pro-healing matrix.

4. Limbal stem cell transplantation (CLET/SLET) – Use: Only for limbal stem cell deficiency, which PACD does not cause. Mechanism: Replaces deficient corneal epithelial stem cells. (Not indicated for PACD.)

5. Intrastromal corneal stromal stem cells / exosomes (research) – Status: Investigational; no clinical dosing standards; not approved for PACD. Mechanism: May modulate stromal matrix and healing—future possibility only.

6. Gene-directed therapy (research horizon) – Since PACD relates to 12q21.33 deletions affecting SLRP genes, future gene or matrix-repair strategies are speculative and not available clinically today. PLOSPMC

Safety note: Do not start any “stem-cell” or “immune booster” therapy without a regulated clinical trial or a cornea specialist’s guidance.

---

Surgeries

Surgery is uncommon in PACD because many cases are mild and stable. When clarity is significantly reduced and lenses no longer help, surgeons consider:

1. Penetrating keratoplasty (PK, full-thickness corneal transplant)
   Why: For visually significant, deep posterior opacities that limit daily life.
   What happens: The cloudy cornea is replaced with a donor cornea.
   Notes: Standard risks include rejection, infection, astigmatism; long-term follow-up needed. EyeWiki

2. Deep anterior lamellar keratoplasty (DALK)
   Why: To replace diseased stroma while keeping your own endothelium (helpful if the endothelium is healthy).
   What happens: The surgeon removes anterior/deep stroma down to Descemet’s membrane.
   Notes: In PACD (posterior stroma involved), very deep dissection is needed; candidacy is individualized.

3. Superficial excimer laser ablation / PTK (as a temporizing measure)
   Why: Rarely used in PACD; may help temporarily if superficial haze contributes or if transplant isn’t available.
   What happens: Laser polishes superficial cornea.
   Notes: Because PACD is posterior, benefits are limited/temporary. EyeWiki

4. Cataract surgery (if a cataract develops)
   Why: To restore clarity from lens opacity (separate from PACD).
   Notes: Pre-op planning considers unusual corneal curvature/flattening to pick the best lens power.

5. Keratoprosthesis (artificial cornea, e.g., Boston KPro), last resort
   Why: For severe cases with multiple graft failures or unsuitable for grafts.
   Notes: High-maintenance solution with significant long-term care; rarely needed in PACD.

---

Prevention tips

There’s no proven way to prevent PACD, and primary prevention is not currently available. You can reduce day-to-day problems and risks:

1. Regular eye exams (track stability; update prescriptions). EyeWiki

2. Family screening/genetic counseling if PACD runs in the family. PLOS

3. UV-blocking sunglasses outdoors.

4. Avoid eye rubbing (can worsen irritation and blur).

5. Use protective eyewear for sports/DIY.

6. Keep contact lenses clean and schedules strict (avoid overwear).

7. Manage allergies to reduce rubbing/tearing.

8. Optimize work lighting to reduce glare and strain.

9. Stay hydrated, sleep well (tear film quality).

10. Don’t undergo refractive surgery (LASIK/PRK) for PACD unless a cornea specialist explicitly clears it—generally not recommended in thin/flat corneas.

---

When to see a doctor

• Immediately: sudden drop in vision, severe eye pain, light sensitivity with redness, trauma, or signs of infection (pus, intense discharge).

• Soon (days): increasing glare/halos that affect driving or work; new contact lens intolerance; frequent headaches or eye strain.

• Routine: regular annual (or specialist-recommended) visits for refraction, imaging (topography/AS-OCT), and counseling—earlier if symptoms change. EyeWiki

---

What to eat & what to avoid

Eat more of:

1. Leafy greens (spinach, kale: lutein/zeaxanthin).

2. Colorful veggies/fruit (vitamin C, antioxidants).

3. Oily fish (salmon, sardines: omega-3s) or algal omega-3 if vegetarian.

4. Nuts/seeds (vitamin E, healthy fats).

5. Whole grains & legumes (minerals and B-vitamins).

Limit/avoid:

1. Smoking (harms ocular surface and overall eye health).
2. Excess alcohol (dehydrates the body/tear film).
3. Ultra-processed, high-salt snacks (worsen dehydration; no PACD-specific benefit).
4. Megadoses of vitamin A or zinc without medical advice (toxicity risk).
5. Any supplement that claims to “cure” PACD (misleading).

Diet supports overall eye surface comfort and health. It doesn’t reverse PACD, but it can make lens wear and day-to-day comfort easier.

---

Frequently Asked Questions (FAQ)

1. Is PACD common?
   No. It is very rare. Many clinicians will never see a case. rarediseases.info.nih.gov

2. Is it inherited?
   Most reported families show autosomal dominant inheritance (50% chance to pass to children). Genetic counseling is reasonable. PubMed

3. What causes it?
   A contiguous gene deletion on 12q21.33 removing several SLRP genes (KERA, LUM, DCN, EPYC) is strongly associated. These genes help organize corneal collagen. PLOSTaylor & Francis Online

4. Does it get worse over time?
   Many cases are non-progressive or slowly progressive. Your eye doctor tracks changes with exams and imaging. EyeWiki

5. Why do I have glare or halos?
   The sheet-like opacities scatter light inside the cornea, especially at night. rarediseases.info.nih.gov

6. Why am I more far-sighted?
   PACD often causes corneal flattening, which can shift your prescription toward hyperopia. EyeWiki

7. Can glasses fix it?
   Glasses can sharpen vision if the main issue is refractive error. If irregularity dominates, RGP or scleral lenses usually give better clarity. Modern Optometry

8. Do eye drops cure PACD?
   No. Drops can improve comfort and tear stability, but they do not remove the posterior sheet opacities.

9. Is corneal cross-linking helpful?
   No evidence supports cross-linking for PACD. Cross-linking is for ectatic corneas (like keratoconus), which is different from PACD’s posterior stromal dystrophy.

10. Will I need a transplant?
    Most do not. If vision is significantly reduced and lenses don’t help, a corneal transplant (PK) may be considered. EyeWiki

11. Can surgery fully restore normal vision?
    Transplant can improve clarity, but outcomes vary, and transplants require lifelong follow-up and care.

12. Is there a genetic test?
    Some labs can test for 12q21.33 microdeletions (copy-number analysis). Talk to a genetics professional about whether testing is appropriate. PLOS

13. Is PACD the same as other “posterior” dystrophies?
    No. For example, posterior polymorphous corneal dystrophy affects the endothelium differently and is managed differently. NCBI

14. Can children be affected?
    Yes—because it’s inherited, children in affected families may have signs early. Pediatric assessment is advisable. PubMed

15. What research is happening?
    The genetic basis (SLRP gene deletion) is now well described; future research may explore matrix biology and gene- or cell-based strategies. No clinical disease-modifying therapy is available yet. PLOSPMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 22, 2025.

PDF Document For This Disease Conditions References